Skip to main content
Journal cover image

Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.

Publication ,  Journal Article
Katz, M; Califf, RM; Sun, J-L; McMurray, JJV; Thomas, L; Lopes, RD
Published in: Am J Med
March 2015

BACKGROUND: Contemporary studies suggest an association between venous thromboembolism and a higher incidence of major cardiovascular events, mostly attributed to arterial atherothrombosis. Using data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, we assessed the association of venous thromboembolism with major cardiovascular events. METHODS: In NAVIGATOR, patients with impaired glucose tolerance were randomly allocated to receive valsartan or placebo and nateglinide or placebo in addition to lifestyle modification. Baseline characteristics and prior history of venous thromboembolism were assessed. After adjusting for important baseline covariates, Cox proportional hazards regression models were used to assess the association between venous thromboembolism and major cardiovascular outcomes. RESULTS: Of the 9306 patients enrolled, 129 (1.4%) had a history of venous thromboembolism. Patients with venous thromboembolism were older, more frequently white and female, and had a higher body mass index. Patients with venous thromboembolism had higher 5-year event rates for the composite of death, myocardial infarction, and stroke, as compared with patients without venous thromboembolism (10.7% vs 5.9%; P < .001; adjusted hazard ratio 2.12; 95% confidence interval, 1.36-3.31; P = .001). CONCLUSION: In patients with impaired glucose tolerance at high risk for cardiovascular events, the prevalence of venous thromboembolism was rare but associated with worse long-term cardiovascular outcomes, including arterial events. Venous thromboembolism is a marker of risk, and attention should be paid to this high-risk group of patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Med

DOI

EISSN

1555-7162

Publication Date

March 2015

Volume

128

Issue

3

Start / End Page

297 / 302

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Valsartan
  • Valine
  • Time Factors
  • Tetrazoles
  • Risk Factors
  • Risk Assessment
  • Proportional Hazards Models
  • Prevalence
  • Phenylalanine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Katz, M., Califf, R. M., Sun, J.-L., McMurray, J. J. V., Thomas, L., & Lopes, R. D. (2015). Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. Am J Med, 128(3), 297–302. https://doi.org/10.1016/j.amjmed.2014.08.022
Katz, Marcelo, Robert M. Califf, Jie-Lena Sun, John J. V. McMurray, Laine Thomas, and Renato D. Lopes. “Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.Am J Med 128, no. 3 (March 2015): 297–302. https://doi.org/10.1016/j.amjmed.2014.08.022.
Katz M, Califf RM, Sun J-L, McMurray JJV, Thomas L, Lopes RD. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. Am J Med. 2015 Mar;128(3):297–302.
Katz, Marcelo, et al. “Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.Am J Med, vol. 128, no. 3, Mar. 2015, pp. 297–302. Pubmed, doi:10.1016/j.amjmed.2014.08.022.
Katz M, Califf RM, Sun J-L, McMurray JJV, Thomas L, Lopes RD. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. Am J Med. 2015 Mar;128(3):297–302.
Journal cover image

Published In

Am J Med

DOI

EISSN

1555-7162

Publication Date

March 2015

Volume

128

Issue

3

Start / End Page

297 / 302

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Valsartan
  • Valine
  • Time Factors
  • Tetrazoles
  • Risk Factors
  • Risk Assessment
  • Proportional Hazards Models
  • Prevalence
  • Phenylalanine